Wapnick Pamela
Chief Financial Officer
Wapnick Pamela has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 10, 2026.
On the most recent filing, Wapnick Pamela is listed as Chief Financial Officer at Metagenomi Therapeutics, Inc. Inside the rolling window, Wapnick Pamela reported no open-market purchases and 5 open-market sales totaling $14K in MGX. The largest disclosed transaction in the window is a sale of 2,884 MGX shares on Jun 5, 2026, worth $4K.
Companies traded
Other insiders at MGX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$14K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Wapnick Pamela made?
Wapnick Pamela has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Wapnick Pamela trade?
Wapnick Pamela has filed SEC Form 4 disclosures for 1 company, including MGX.
When was Wapnick Pamela's most recent SEC Form 4 filing?
Wapnick Pamela's most recent SEC Form 4 filing on Tracefour is dated Sep 10, 2026.
What is Wapnick Pamela's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Wapnick Pamela is listed as Chief Financial Officer.
What is Wapnick Pamela's total buy and sell value in the current window?
Inside the rolling retention window, Wapnick Pamela bought $0 and sold $14K based on SEC Form 4 filings.
What was Wapnick Pamela's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,884 MGX shares on 2026-06-05, worth $4K, per SEC Form 4 filings.